EE181 An Economic Model to Estimate Costs of Cytokine Release Syndrome (CRS) and Neurological Events (NE) Among Patients Treated with Lisocabtagene Maraleucel (LISO-CEL) or Axicabtagene Ciloleucel (AXI-CEL) for Second-LINE (2L) Treatment of ...

Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.430
https://www.valueinhealthjournal.com/article/S1098-3015(22)00631-3/fulltext
Title : EE181 An Economic Model to Estimate Costs of Cytokine Release Syndrome (CRS) and Neurological Events (NE) Among Patients Treated with Lisocabtagene Maraleucel (LISO-CEL) or Axicabtagene Ciloleucel (AXI-CEL) for Second-LINE (2L) Treatment of ...
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)00631-3&doi=10.1016/j.jval.2022.04.430
First page :
Section Title :
Open access? : No
Section Order : 10375
Categories :
Tags :
Regions :
ViH Article Tags :